Sachetta LLC Sells 399 Shares of Bristol Myers Squibb Company $BMY

Sachetta LLC lessened its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 27.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,067 shares of the biopharmaceutical company’s stock after selling 399 shares during the quarter. Sachetta LLC’s holdings in Bristol Myers Squibb were worth $49,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Harel Insurance Investments & Financial Services Ltd. bought a new position in Bristol Myers Squibb in the 1st quarter valued at about $31,000. Accent Capital Management LLC bought a new position in Bristol Myers Squibb in the 1st quarter valued at about $33,000. CBIZ Investment Advisory Services LLC lifted its position in Bristol Myers Squibb by 66.0% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 231 shares in the last quarter. GKV Capital Management Co. Inc. bought a new position in Bristol Myers Squibb in the 1st quarter valued at about $36,000. Finally, EQ Wealth Advisors LLC bought a new position in Bristol Myers Squibb in the 1st quarter valued at about $37,000. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Down 1.1%

Bristol Myers Squibb stock opened at $44.63 on Wednesday. Bristol Myers Squibb Company has a 1-year low of $42.96 and a 1-year high of $63.33. The firm has a market capitalization of $90.84 billion, a price-to-earnings ratio of 18.00, a P/E/G ratio of 2.31 and a beta of 0.33. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. The firm has a 50 day simple moving average of $46.27 and a 200 day simple moving average of $48.36.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, beating analysts’ consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The business had revenue of $12.27 billion during the quarter, compared to analyst estimates of $11.32 billion. During the same period in the previous year, the business earned $2.07 EPS. Bristol Myers Squibb’s revenue was up .6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Friday, October 3rd will be paid a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 5.6%. The ex-dividend date is Friday, October 3rd. Bristol Myers Squibb’s payout ratio is currently 100.00%.

Insiders Place Their Bets

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the transaction, the executive vice president directly owned 167,379 shares of the company’s stock, valued at $7,922,048.07. This trade represents a 25.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on BMY. Daiwa America lowered shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 5th. Morgan Stanley reiterated a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Dbs Bank upgraded shares of Bristol Myers Squibb to a “moderate buy” rating in a research note on Thursday, October 2nd. Citigroup decreased their price objective on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating for the company in a research note on Friday, August 1st. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Bristol Myers Squibb in a research note on Saturday, September 27th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and fifteen have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $57.14.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.